Clearside reports Q1 net loss $11.8M, $0.17/sh; cash $35.4M; ODYSSEY topline due Q3 2024

Clearside Biomedical, Inc.

2024-Q1 EPS reported -$0.17 revenue$230,000

Net loss $11.8M ($0.17/sh) vs $9.3M ($0.15) Q1 2023; revenue $230K up from $4K.
Cash $35.4M expected to fund operations into Q3 2025.
Phase 2b ODYSSEY trial of CLS-AX in wet AMD topline data expected Q3 2024.
Appointed Victor Chong as CMO (March 2024) and Tony Gibney to Board (April 2024).
Completed $15M registered direct offering in Feb 2024; new CPT code for XIPERE effective Jan 1, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Clearside Biomedical, Inc. reported first quarter ended March 31, 2024 results: revenue $230,000, net income $11.8 million, EPS $0.17 per share of common stock.

Period: first quarter ended March 31, 2024
Revenue: $230,000
Net income: $11.8 million
EPS: $0.17 per share of common stock
Result: reported results

Exact text from the filing

by delivering drug directly to the back of the eye via the SCS Microinjector. First Quarter 2024 Financial Results • License and other revenue for the first quarter of 2024 was $230,000, compared to $4,000 for the first quarter of 2023. • Research and development expenses for the first quarter of 2024 were $5.6 million, compared to $4.5 million for the first

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056958

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.